Core Insights - The company reported a revenue of RMB 7.519 billion for the six months ending June 30, 2025, representing a year-on-year increase of 4.8% [1] - Profit attributable to shareholders reached RMB 1.894 billion, marking a year-on-year increase of 27% [1] - Basic earnings per share were RMB 1.0426, with an interim dividend proposed at RMB 0.16 per share [1] Revenue Breakdown - Revenue from intermediates, active pharmaceutical ingredients (APIs), and formulation products were RMB 2.304 billion, RMB 2.999 billion, and RMB 3.9785 billion, respectively, showing year-on-year changes of -25.2%, -23.4%, and +65.9% [1] - Segment profits for intermediates, APIs, and formulation products were RMB 634.6 million, RMB 250.6 million, and RMB 1.5056 billion, reflecting year-on-year changes of -40.6%, -52.0%, and +524.2% [1]
联邦制药(03933)发布中期业绩，股东应占溢利18.94亿元 同比增加27%